Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 4/20 | 0.53 |
| ▸ | PDE4A | P27815 | 4/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8326986 | 0.95 | NOS1 (0.54) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3960231 | 0.89 | CYP2C9 (0.57) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4719992 | 0.83 | NUDT1 (0.53) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7197832 | 0.82 | GPR84 (0.43) | POLBHCAR2 | |
| SCHEMBL2314765 | 0.82 | DDAH1 (0.55) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9597011 | 0.79 | CYP2C9 (0.53) | PDE5ACYP2C9NOS1NOS2NUDT1 | |
| SCHEMBL9570423 | 0.79 | CYP2C9 (0.53) | PDE5ACYP2C9NOS1NOS2NUDT1 | |
| SCHEMBL10952467 | 0.78 | PI4KA (0.44) | NOS1NOS2PI4KAPI4K2BPI4K2A | |
| SCHEMBL7002580 | 0.78 | NUDT1 (0.58) | PDE5ACYP2C9NOS1NOS2NUDT1 | |
| SCHEMBL9705822 | 0.78 | PARP1 (0.46) | PDE5APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0072926-B1 | 2-ARYLIMIDAZOPYRIDINES | MERCK PATENT GmbH (DE) | 1986-09-24 | — | — | EP | claimed |
| EP-0072926-A1 | 2-Arylimidazopyridines | MERCK PATENT GmbH (DE) | 1983-03-02 | — | — | EP | claimed |
| EP-1986750-B1 | Use of an extract of Enanthia Chloranta | SEDERMA SA (FR) | 2019-04-24 | — | — | EP | disclosed |
| US-8846019-B2 | Use of protoberberines as an active substance regulating the pilosebaceous unit | SEDERMA (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8591874-B2 | Inhibition of mammalian hair growth | THE PROCTER & GAMBLE COMPANY (US) | 2013-11-26 | — | — | US | disclosed |
| US-8481015-B2 | Applying agmatine and a dermatologically acceptable carrier to the skin; inhibiting hair growth | THE PROCTER & GAMBLE COMPANY (US) | 2013-07-09 | — | — | US | disclosed |
| US-8198299-B2 | Cycloalkylidene and heterocycloalkylidene inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-8088771-B2 | Cycloalkylidene and heterocycloalkylidene inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2326622-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE HISTONE DEACETYLASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-06-01 | — | — | EP | disclosed |
| US-4873251-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANTIANXIETY AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-10-10 | — | — | US | disclosed |
| US-4824951-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANXIOLYTIC AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-04-25 | — | — | US | disclosed |
| US-4772600-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANXIOLYTIC | A. H. ROBINS COMPANY, INC. (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0256402-A2 | Pharmaceutical preparation | MERCK PATENT GmbH (DE) | 1988-02-24 | — | — | EP | disclosed |
| EP-0255217-A1 | Fused imidazoheterocyclic compounds | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-02-03 | — | — | EP | disclosed |
| EP-0072926-B1 | 2-ARYLIMIDAZOPYRIDINES | MERCK PATENT GmbH (DE) | 1986-09-24 | — | — | EP | disclosed |
| EP-0072926-B1 | 2-ARYLIMIDAZOPYRIDINES | MERCK PATENT GmbH (DE) | 1986-09-24 | — | — | EP | disclosed |
| EP-0072926-A1 | 2-Arylimidazopyridines | MERCK PATENT GmbH (DE) | 1983-03-02 | — | — | EP | disclosed |
| EP-0072926-A1 | 2-Arylimidazopyridines | MERCK PATENT GmbH (DE) | 1983-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | PDE5A 2695/4885PDE4A 2248/4885PDE4B 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.